Skip to main content
SpringerLink
Log in

m-AMSA: A New Anticancer Agent

  • Chapter
Cancer Chemo- and Immunopharmacology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 74))

Summary

4’-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA; NSC-249992) is a new anticancer agent that has undergone extensive experimental investigation. Clinical trials have recently been initiated and current data suggest a wide spectrum of antitumor activity in human cancer.

This work was supported by grant 3.4535.79 from the “Fonds de la Recherche Scientifique Médicale” (FNRS, Belgium), and by contract NIH NO1/CM53840 from the National Cancer Institute, Bethesda, Maryland, USA

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer 10:539–549

    Article  PubMed  CAS  Google Scholar 

  2. Corbett TH, Griswold DP Jr Roberts BJ, Peckham JC, Schabel FM Jr (1977) Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660–2680

    Article  PubMed  CAS  Google Scholar 

  3. Cysyk RL, Shoemaker D, Adamson RH (1977) The pharmacologic disposition of 4’-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats. Drug Metab Dispos 5:579–590

    PubMed  CAS  Google Scholar 

  4. Cysyk RL, Shoemaker D, Ayers OC, Adamson RH (1978) Oral absorption and selective tissue localization of 4’-(9-acridinylamino)-methanesulfon-m-anisidide. Pharmacology 16:206–213

    Article  PubMed  CAS  Google Scholar 

  5. Deaven LL, Oka MS, Tobey RA (1978) Cell-cycle-specific chromosome damage following treatment of cultured Chinese hamster cells with 4’-[(9-acridinyl)-amino]methanesul- phon-m-anisidide-HCl. J Natl Cancer Inst 60:1155–1161

    PubMed  CAS  Google Scholar 

  6. DeJager R, Body JJ, Dupont D, Klastersky J, Kenis Y (1979) Phase I study of oral 4’-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA, NSC 249992). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:429

    Google Scholar 

  7. Furlong NB, Sato J, Brown T, Chavez F, Hurlbert RB (1978) Induction of limited DNA damage by the antitumor agent Cain’s acridine. Cancer Res 38:1329–1335

    PubMed  CAS  Google Scholar 

  8. Goldsmith MA, Bhardwaj S, Ohnuma T, Greenspan EM, Holland JF (1979) Phase I study of m-AMSA in patients with solid tumors and leukemias. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:344

    Google Scholar 

  9. Gormley PE, Sethi VS, Cysyk RL (1978) Interaction of 4’-(9-acridinylamino)methane- sulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases. Cancer Res 38:1300–1306

    PubMed  CAS  Google Scholar 

  10. Hall SW, Benjamin RS, Legha SS, Gutterman JU, Burgess MA, Bodey GP (1979) AMSA: A new acridine derivative with activity against metastatic melanoma. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:372

    Google Scholar 

  11. Hall SW, Benjamin RS, Legha SS, Gutterman JU, Loo TL (1979) Clinical pharmacokinetics of the new antitumor agent AMSA. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:175

    Google Scholar 

  12. Johnson RK, Chitnis MP, Goldin A (1976) Characteristics of resistance and cross-resistance in vivo of a subline of P388 leukemia resistant to adriamycin. Pharmacologist 18:173

    Google Scholar 

  13. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Bodey GP (1979) Phase II study of 4’-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep 63:1961–1964

    PubMed  CAS  Google Scholar 

  14. Legha SS, Bodey GP, Keating MJ, Blumenschein GR, Hortobagyi GN, Buzdar AU, McCredie K, Freireich EJ (1979) Early clinical evaluation of acridinylamino-methanesul- fon-ra-anisidide (AMSA) in patients with advanced breast cancer and acute leukemia. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:416

    Google Scholar 

  15. Legha SS, Gutterman JU, Hall SW, Benjamin RS, Burgess MA, Valdivieso M, Bodey GP (1978) Phase I clinical investigation of 4’-(9-acridinylamino)methanesulfon-m-anisidide (NSC-249992), a new acridine derivative. Cancer Res 38:3712–3716

    PubMed  CAS  Google Scholar 

  16. Malspeis L, Khan MN, Blat HB (1979) HPLC determination of 4’-(9acridinyl-amino-meth- anesulfon)m-anisidide (m-AMSA; NSC 249992) in the plasma of a patient with hepatic dysfunction. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:384

    Google Scholar 

  17. Mellanby E (1933) Report on work carried out in the pharmacological laboratory, Sheffield University. British Empire Cancer Campaign 10th Annual Report, pp 102–103

    Google Scholar 

  18. Osieka, R, Houchens DP, Goldin A, Johnson RK (1977) Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 40:2640–2650

    Article  PubMed  CAS  Google Scholar 

  19. Schneider R, Sklaroff R, Ochoa M Jr, Young C (1979) Phase I trial of AMSA [4’-(9-acridinylamino)-methanesulfon-m-anisidide]. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:114

    Google Scholar 

  20. Shoemaker D, Ayer O, D’Anna M, Cysyk R (1979) Effect of diethyl maleate and phenobarbital on the metabolism and biliary excretion of 4’-(9-acridinylamino)-methane- sulfon-m-anisidide (m-AMSA; NSC-141549) in rats. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:280

    Google Scholar 

  21. Shoemaker DD, Legha SS, Cysyk RL (1978) Selective localization of 4’-(9-acridinylami- no)methanesulfon-m-anisidide in B16 melanoma. Pharmacology 16:221–225

    Article  PubMed  CAS  Google Scholar 

  22. Tan C, Haghbin M, Rosen G, Miller DR (1979) Acridinylamino anisidide (AMSA) in children with advanced cancer. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:154

    Google Scholar 

  23. Tobey RA, Deaven LL, Oka MS (1978) Kinetic response of cultured Chinese hamster cells to treatment with 4’-[(9-acridinyl)amino]methanesulphon-m-anisidide-HCl. J Natl Cancer Inst 60:1147–1153

    PubMed  CAS  Google Scholar 

  24. Van Echo DA, Gormley P, Lichtenfeld JL, Scoltock M, Wiernik PH (1979) A phase I study of m-AMSA. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 20:422

    Google Scholar 

  25. Von Hoff DD, Howser D, Gormley P, Bender RA, Glaubiger D, Levine AS, Young RC (1978) Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl] -(m-AMSA) using a single-dose schedule. Cancer Treat Rep 62:1421–1426

    Google Scholar 

  26. Waring MJ (1976) DNA-binding characteristics of acridinylmethanesulphonanilide drugs: Comparison with antitumour properties. Eur J Cancer 12:995–1001

    Article  PubMed  CAS  Google Scholar 

  27. Wilson WR (1973) Studies on mechanism of action of an experimental antitumor drug. Chem NZ 37:148–152

    CAS  Google Scholar 

Download references

Authors
  1. M. Rozencweig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. S. Legha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. L. Cysyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. M. Muggia
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut de Cancérologie et Immunogénétique, Hôpital Paul-Brousse, 14 - 16 Avenue Paul-Vaillant-Couturier, F-94800, Villejuif, France

    Georges Mathé

  2. Medical Center, Division of Oncology, Department of Internal Medicine, Institute of Environmental Medicine, New York University, 550 First Avenue, 10016, New York, NY, USA

    Franco M. Muggia

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rozencweig, M., Von Hoff, D.D., Legha, S.S., Cysyk, R.L., Muggia, F.M. (1980). m-AMSA: A New Anticancer Agent. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81488-4_29

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81490-7

  • Online ISBN: 978-3-642-81488-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation